Qiming Venture Partners

AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, the company aims to enhance targeted delivery technologies to improve treatment outcomes. AusperBio is dedicated to addressing a variety of diseases, including viral infections, genetic disorders, metabolic conditions, and immune diseases, through its small interfering ribonucleic acid (siRNA) drugs. By concentrating on effective treatment strategies and vaccination for chronic hepatitis B, AusperBio seeks to provide patients with improved therapeutic options and protection against this challenging disease.

BioHeng is a clinical biopharmaceutical and biotechnology Company focuses on novel immunotherapy and next-generation gene therapy development for treating cancers and various diseases. Founded in 2017, Bioheng has established a high standard GMP grade clinical translational center, and is leading in the field of cell engineering, proliferation and clinical applications. Particularly, Bioheng owns several cutting-edge patents plus extensive industry experience, and has built a complete, closed and automated production system in compliance with regulatory guidelines. In 2018, Bioheng has successfully raised tens of millions of RMB seeding fund from Simcere Pharmaceutical Group, aiming to accelerate the development of immunotherapy via integrating resources from both parties. Bioheng is dedicated to develop safer, effective and less expensive cell therapy drugs to benefit more patients.

GenEditBio is a biotechnology company that focuses on developing gene editing drugs to address unmet medical needs associated with genetic diseases. The company specializes in innovative research and the advancement of in vivo gene editing tools, along with related delivery systems. By providing curative solutions, GenEditBio aims to improve treatment options for patients suffering from genetic disorders.

Sanegene Bio is engaged in the development of RNA interference (RNAi) therapeutics aimed at addressing unmet clinical needs across various therapeutic areas. The company’s RNAi drug discovery platform focuses on effectively knocking down disease-causing genes, utilizing advanced RNA technology to ensure specific delivery of multiple RNA drugs. This innovative approach allows for targeted treatment of patients suffering from a range of conditions, including cardiovascular and metabolic diseases, immunology-related diseases, infectious diseases, and disorders affecting the central nervous system and eyes. Through its comprehensive RNAi portfolio, Sanegene Bio seeks to provide effective therapeutic solutions for challenging health issues.

Complete Omics is a developer focused on multi-omics diagnostics aimed at the early detection of diseases, particularly cancer. The company specializes in personalized diagnosis and treatment, leveraging patented technologies across various omics fields. By offering precision companion diagnostics, Complete Omics enables researchers and pharmaceutical companies to conduct highly sensitive and specific health surveillance tests, facilitating improved patient outcomes through tailored medical interventions.

Biotree is a high-tech enterprise focused on the application and development of advanced research technology in the life sciences sector. It specializes in metabolomics, offering early detection and analysis services in China. The company boasts a core team with significant expertise in metabolomics, encompassing scientific research services, health testing, and industrial testing. Biotree emphasizes mass spectrometry and metabolic testing, continually innovating in metabolomics products and technologies. It holds several patents in this field and is recognized for its accomplishments in metabolomics detection and analysis. Over the years, Biotree has demonstrated consistent growth and has maintained profitability for six consecutive years, solidifying its position in the biotechnological testing and consulting services market.

Sanegene Bio is engaged in the development of RNA interference (RNAi) therapeutics aimed at addressing unmet clinical needs across various therapeutic areas. The company’s RNAi drug discovery platform focuses on effectively knocking down disease-causing genes, utilizing advanced RNA technology to ensure specific delivery of multiple RNA drugs. This innovative approach allows for targeted treatment of patients suffering from a range of conditions, including cardiovascular and metabolic diseases, immunology-related diseases, infectious diseases, and disorders affecting the central nervous system and eyes. Through its comprehensive RNAi portfolio, Sanegene Bio seeks to provide effective therapeutic solutions for challenging health issues.

PlusLife Biotech, founded in 2017 and based in Guangzhou, China, focuses on creating innovative molecular diagnostic tools and gene treatment programs utilizing advanced gene technology. The company has developed a range of molecular point-of-care testing (POCT) detection cards and reagents designed for diverse applications, including human respiratory and reproductive tract infections, genotype detection, and pet disease detection. PlusLife Biotech aims to provide customers with cost-effective and user-friendly testing solutions, enhancing the accessibility and efficiency of medical diagnostics.

Biotree is a high-tech enterprise focused on the application and development of advanced research technology in the life sciences sector. It specializes in metabolomics, offering early detection and analysis services in China. The company boasts a core team with significant expertise in metabolomics, encompassing scientific research services, health testing, and industrial testing. Biotree emphasizes mass spectrometry and metabolic testing, continually innovating in metabolomics products and technologies. It holds several patents in this field and is recognized for its accomplishments in metabolomics detection and analysis. Over the years, Biotree has demonstrated consistent growth and has maintained profitability for six consecutive years, solidifying its position in the biotechnological testing and consulting services market.

Ceptur Therapeutics is focused on developing innovative genetic medicines aimed at addressing diseases that currently lack effective treatments. The company utilizes its proprietary U1 Adaptor technology, which enables long-lasting and non-genotoxic silencing of disease-causing genes, particularly in challenging tissues beyond the liver and central nervous system. This technology addresses the limitations of existing gene silencing methods and holds promise for cancer treatment, allowing healthcare providers to offer new therapeutic options for patients with various types of cancers.

Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.

GenEdit Inc., founded in 2016 and based in Berkeley, California, focuses on advancing gene therapy through its innovative genome editing tools, particularly the CRISPR/Cas9 system. The company aims to address the challenges associated with gene therapy delivery by utilizing its proprietary NanoGalaxy™ platform, which systematically screens a library of nanoparticles to enhance the safety and efficiency of delivering genetic material to target tissues. GenEdit's technology is designed to facilitate therapeutic gene editing, offering a solution that is easier, faster, and more accurate than traditional methods. This positions GenEdit to potentially enable the treatment of previously incurable genetic diseases, significantly contributing to the future of non-viral, gene editing-based therapeutics.

Genevide is a biotech company founded in 2019 and based in Suzhou, Jiangsu, China, focusing on gene research and development. The company has developed a molecular enzyme cycle screening platform designed to address challenges in nucleic acid detection. Its key technologies include enzyme-mediated one-step sample processing and enzyme-mediated double exponential amplification, which facilitate efficient nucleic acid detection for researchers. Genevide aims to provide innovative solutions that make nucleic acid detection more accessible and effective.

Sanegene Bio is engaged in the development of RNA interference (RNAi) therapeutics aimed at addressing unmet clinical needs across various therapeutic areas. The company’s RNAi drug discovery platform focuses on effectively knocking down disease-causing genes, utilizing advanced RNA technology to ensure specific delivery of multiple RNA drugs. This innovative approach allows for targeted treatment of patients suffering from a range of conditions, including cardiovascular and metabolic diseases, immunology-related diseases, infectious diseases, and disorders affecting the central nervous system and eyes. Through its comprehensive RNAi portfolio, Sanegene Bio seeks to provide effective therapeutic solutions for challenging health issues.

PlusLife Biotech, founded in 2017 and based in Guangzhou, China, focuses on creating innovative molecular diagnostic tools and gene treatment programs utilizing advanced gene technology. The company has developed a range of molecular point-of-care testing (POCT) detection cards and reagents designed for diverse applications, including human respiratory and reproductive tract infections, genotype detection, and pet disease detection. PlusLife Biotech aims to provide customers with cost-effective and user-friendly testing solutions, enhancing the accessibility and efficiency of medical diagnostics.

Abogen Biosciences, established in 2019 and headquartered in Jiangsu, China, specializes in the development of nucleic acid-based therapeutics, including RNA and DNA treatments, for combating cancer and infectious diseases.

Berry Oncology is a medical technology company focused on enhancing cancer prevention and diagnosis through advanced genomic testing solutions. The company offers a range of products and services, including genetic diagnosis, companion diagnostics, and tools for monitoring treatment response and prognosis prediction for various malignant tumors. By addressing clinical challenges associated with cancer detection and management, Berry Oncology aims to facilitate early diagnosis and treatment, ultimately improving patient quality of life and reducing cancer risks. Its mission emphasizes precise treatment for all patients, while its vision seeks to establish the company as a leader in early screening and diagnosis within the global market, particularly in China's tumor gene testing sector.

Abogen Biosciences, established in 2019 and headquartered in Jiangsu, China, specializes in the development of nucleic acid-based therapeutics, including RNA and DNA treatments, for combating cancer and infectious diseases.

Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.

Berry Genomics is a biotechnology company focused on the development and commercialization of genomic technologies for life sciences and clinical applications. The company specializes in next generation sequencing (NGS) tests aimed at detecting genetic diseases and cancers throughout various life stages, from preconception to adulthood. In addition to its testing services, Berry Genomics offers gene sequencing detection equipment, contributing to advancements in genetic research and diagnostics. Through its innovative approach, the company plays a significant role in the evolving field of genomics.

Berry Oncology is a medical technology company focused on enhancing cancer prevention and diagnosis through advanced genomic testing solutions. The company offers a range of products and services, including genetic diagnosis, companion diagnostics, and tools for monitoring treatment response and prognosis prediction for various malignant tumors. By addressing clinical challenges associated with cancer detection and management, Berry Oncology aims to facilitate early diagnosis and treatment, ultimately improving patient quality of life and reducing cancer risks. Its mission emphasizes precise treatment for all patients, while its vision seeks to establish the company as a leader in early screening and diagnosis within the global market, particularly in China's tumor gene testing sector.

Berry Genomics is a biotechnology company focused on the development and commercialization of genomic technologies for life sciences and clinical applications. The company specializes in next generation sequencing (NGS) tests aimed at detecting genetic diseases and cancers throughout various life stages, from preconception to adulthood. In addition to its testing services, Berry Genomics offers gene sequencing detection equipment, contributing to advancements in genetic research and diagnostics. Through its innovative approach, the company plays a significant role in the evolving field of genomics.

Berry Oncology is a medical technology company focused on enhancing cancer prevention and diagnosis through advanced genomic testing solutions. The company offers a range of products and services, including genetic diagnosis, companion diagnostics, and tools for monitoring treatment response and prognosis prediction for various malignant tumors. By addressing clinical challenges associated with cancer detection and management, Berry Oncology aims to facilitate early diagnosis and treatment, ultimately improving patient quality of life and reducing cancer risks. Its mission emphasizes precise treatment for all patients, while its vision seeks to establish the company as a leader in early screening and diagnosis within the global market, particularly in China's tumor gene testing sector.

Berry Genomics is a biotechnology company focused on the development and commercialization of genomic technologies for life sciences and clinical applications. The company specializes in next generation sequencing (NGS) tests aimed at detecting genetic diseases and cancers throughout various life stages, from preconception to adulthood. In addition to its testing services, Berry Genomics offers gene sequencing detection equipment, contributing to advancements in genetic research and diagnostics. Through its innovative approach, the company plays a significant role in the evolving field of genomics.

BBI Life Sciences Corporation is a prominent provider of life sciences products and services, headquartered in Shanghai, China. Incorporated in 2013, it develops, manufactures, and sells a diverse range of offerings that support scientific research across various regions, including China, North America, South America, Europe, and Africa. The company operates through five main segments: DNA Synthesis Products, Genetic Engineering Services, Life Science Research Consumables, Protein and Antibody Related Products and Services, and Third Party Detection. Its DNA Synthesis Products include oligonucleotides and gene synthesis used in molecular biology and medical research. The Genetic Engineering Services segment offers DNA sequencing and gene analysis, while the Life Science Research Consumables segment supplies biochemical reagents and laboratory tools. The Protein and Antibody segment features kits and services related to protein detection and analysis, along with customized antibody production. Additionally, BBI Life Sciences provides medical detection and diagnosis services. With a strong client base that includes educational institutions, research institutes, hospitals, and biotech companies, the company has established itself as a leader in the life sciences market in China and beyond.

Amoy Diagnostics is a research and development based diagnostic company focusing on molecular diagnostics for oncology precision medicine. AmoyDx has a portfolio of molecular diagnostic assays. Based on multiple technology platforms including PCR, NGS, FISH and IHC, AmoyDx's core product categories include single gene testing kits, multi-gene testing panels, NGS panels, and NGS analytical systems.

Crown Bioscience International, through its subsidiary Crown Bioscience Inc., is a global company specializing in drug discovery and development solutions. Founded in 2006 and based in Taipei, Taiwan, the company focuses on providing translational platforms for oncology, cardiovascular, and metabolic diseases, helping biopharmaceutical companies enhance drug efficacy and patient response while minimizing clinical failures. Crown Bioscience offers a comprehensive range of products, including antibodies for in vivo and in vitro studies, recombinant proteins, and tumor tissue microarrays, as well as integrated preclinical testing services. The firm has established strategic partnerships, including collaborations with the Shanghai Model Organisms Center and Hubrecht Organoid Technology, to advance its capabilities in genetically engineered models and organoid-based preclinical drug development. With facilities in the United States, United Kingdom, China, and Taiwan, Crown Bioscience serves the biotech and pharmaceutical industries worldwide, facilitating the acceleration of new drug development programs.

Amoy Diagnostics is a research and development based diagnostic company focusing on molecular diagnostics for oncology precision medicine. AmoyDx has a portfolio of molecular diagnostic assays. Based on multiple technology platforms including PCR, NGS, FISH and IHC, AmoyDx's core product categories include single gene testing kits, multi-gene testing panels, NGS panels, and NGS analytical systems.

Berry Genomics is a biotechnology company focused on the development and commercialization of genomic technologies for life sciences and clinical applications. The company specializes in next generation sequencing (NGS) tests aimed at detecting genetic diseases and cancers throughout various life stages, from preconception to adulthood. In addition to its testing services, Berry Genomics offers gene sequencing detection equipment, contributing to advancements in genetic research and diagnostics. Through its innovative approach, the company plays a significant role in the evolving field of genomics.

OriGene Technologies, Inc. is a biotechnology company based in Rockville, Maryland, specializing in the development, manufacturing, and sale of genome-wide research and diagnostic products. Established in 1995, OriGene offers a comprehensive array of tools for academic, diagnostic, pharmaceutical, and biotech applications. Its product portfolio includes cDNA clones, shRNA and siRNA reagents, CRISPR/Cas9 genome editing tools, proteins, antibodies, and anatomic pathology products. Additionally, the company provides services such as gene synthesis, custom cloning, and assay development, supporting a variety of research areas including cancer biomarker research and stem cell research. OriGene's extensive resources aim to facilitate gene-based research, enabling researchers to validate antibodies and develop new drugs. The company's products are distributed globally through various channels, including online platforms.

Crown Bioscience International, through its subsidiary Crown Bioscience Inc., is a global company specializing in drug discovery and development solutions. Founded in 2006 and based in Taipei, Taiwan, the company focuses on providing translational platforms for oncology, cardiovascular, and metabolic diseases, helping biopharmaceutical companies enhance drug efficacy and patient response while minimizing clinical failures. Crown Bioscience offers a comprehensive range of products, including antibodies for in vivo and in vitro studies, recombinant proteins, and tumor tissue microarrays, as well as integrated preclinical testing services. The firm has established strategic partnerships, including collaborations with the Shanghai Model Organisms Center and Hubrecht Organoid Technology, to advance its capabilities in genetically engineered models and organoid-based preclinical drug development. With facilities in the United States, United Kingdom, China, and Taiwan, Crown Bioscience serves the biotech and pharmaceutical industries worldwide, facilitating the acceleration of new drug development programs.

Sangon Biotech Co. is a biotechnology company founded in 2003 as a Sino-foreign joint venture, specializing in the research and development of chemical synthesis of DNA. Over the years, Sangon has established itself as a key player in the global biotechnology market, known for its expertise in DNA synthesis, sequencing, and gene synthesis. The company has invested significantly in its infrastructure, including a manufacturing and industrial base in Songjiang Industrial Park. Sangon offers a wide range of products and services, including molecular biology kits, biochemicals, synthetic genes, oligos, peptide synthesis, enzymes, and laboratory consumables. By providing affordable life science research tools and services, Sangon supports researchers in advancing basic research and product development in the life sciences field.

Crown Bioscience International, through its subsidiary Crown Bioscience Inc., is a global company specializing in drug discovery and development solutions. Founded in 2006 and based in Taipei, Taiwan, the company focuses on providing translational platforms for oncology, cardiovascular, and metabolic diseases, helping biopharmaceutical companies enhance drug efficacy and patient response while minimizing clinical failures. Crown Bioscience offers a comprehensive range of products, including antibodies for in vivo and in vitro studies, recombinant proteins, and tumor tissue microarrays, as well as integrated preclinical testing services. The firm has established strategic partnerships, including collaborations with the Shanghai Model Organisms Center and Hubrecht Organoid Technology, to advance its capabilities in genetically engineered models and organoid-based preclinical drug development. With facilities in the United States, United Kingdom, China, and Taiwan, Crown Bioscience serves the biotech and pharmaceutical industries worldwide, facilitating the acceleration of new drug development programs.

Crown Bioscience International, through its subsidiary Crown Bioscience Inc., is a global company specializing in drug discovery and development solutions. Founded in 2006 and based in Taipei, Taiwan, the company focuses on providing translational platforms for oncology, cardiovascular, and metabolic diseases, helping biopharmaceutical companies enhance drug efficacy and patient response while minimizing clinical failures. Crown Bioscience offers a comprehensive range of products, including antibodies for in vivo and in vitro studies, recombinant proteins, and tumor tissue microarrays, as well as integrated preclinical testing services. The firm has established strategic partnerships, including collaborations with the Shanghai Model Organisms Center and Hubrecht Organoid Technology, to advance its capabilities in genetically engineered models and organoid-based preclinical drug development. With facilities in the United States, United Kingdom, China, and Taiwan, Crown Bioscience serves the biotech and pharmaceutical industries worldwide, facilitating the acceleration of new drug development programs.

AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, the company aims to enhance targeted delivery technologies to improve treatment outcomes. AusperBio is dedicated to addressing a variety of diseases, including viral infections, genetic disorders, metabolic conditions, and immune diseases, through its small interfering ribonucleic acid (siRNA) drugs. By concentrating on effective treatment strategies and vaccination for chronic hepatitis B, AusperBio seeks to provide patients with improved therapeutic options and protection against this challenging disease.